MagSense HER2
Phase 1- Indications
- HER2-positive breast cancer
Company intelligence / Profile preview
Imagion Biosystems
South Melbourne, Victoria, Australiaimagionbiosystems.com ↗
- Ownership
- Public · IBX
- Development stage
- Phase 1
01
Overview
Imagion Biosystems has completed a multi-site Phase I study of its MagSense® HER2 imaging agent for non-invasive detection of lymph node metastasis in breast cancer. The company has begun manufacturing the agent ahead of a planned Phase II trial. Additional programs targeting ovarian and prostate cancers are at earlier stages. The company’s technology aims to improve early detection and staging of cancers using bio-safe magnetic nanoparticles with standard MRI instruments, without ionizing radiation or radioactive tracers.
- Therapeutic areas
- Oncology
- Modalities
- Nanoparticles (specifically superparamagnetic iron oxide nanoparticles, SPIONs)Molecular imaging agents
- Industry
- Medical Imaging
02
Drug pipeline
1 asset03
Partnerships
Siemens Healthineers Pty Ltd. – collaboration on MagSense® HER2 clinical studies in Australia and USMOU with Prestige Biopharma to develop an early pancreatic cancer diagnostic test.
04
Financials
- Market cap
- $2.2M
- Total revenue
- $0
- Enterprise value
- $3.7M
Beyond the preview
Go deeper on Imagion Biosystems.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imagion Biosystems.